Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVnCoV phase 2b/3 COVID-19 vaccine efficacy and safety trial
NL-OMON50925Phase 3Recruiting
- Sponsor
- CureVac
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing CVnCoV with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint, Primary safety endpoint - medically attended adverse events and 6 more. Started Dec 2020; status: recruiting.
02
Drugs
zorecimeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50925.